Argenta Discovery has announced that it has entered into a drug discovery collaboration with AstraZeneca LP.
Under the terms of the agreement, Argenta scientists will provide their expertise in medicinal chemistry to support drug discovery activities at AstraZeneca in Wilmington, DE.
The new medicinal chemistry programme, announced today, will involve optimisation of a series of hits by the design and synthesis of novel analogues.
Commenting on the agreement, Dr Christopher Ashton, Argenta Discovery's CEO, said, "We are pleased that AstraZeneca has chosen to work with Argenta again".
"This is our first collaboration with AstraZeneca's Wilmington team and we believe their decision to work with Argenta is a tribute to the outstanding capabilities and expertise of Argenta's medicinal chemistry team".
"We look forward to a fruitful collaboration with AstraZeneca Wilmington." Frank Yocca, VP Neuroscience Research, AstraZeneca R and D Wilmington adds, "The collaboration with Argenta is in line with our Discovery organisation's goal of bringing high quality compounds through to Development".
"We believe that Argenta will complement our internal strengths and are confident this will result in a successful collaboration ultimately benefiting the patient." Financial terms of the deal were not disclosed, but the agreement does provide options to expand the relationship.
